Χώρα: Μαλαισία
Γλώσσα: Αγγλικά
Πηγή: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
METHYLPREDNISOLONE SODIUM SUCCINATE
KOTRA PHARMA (M) SDN. BHD.
METHYLPREDNISOLONE SODIUM SUCCINATE
10vial Vials; 1vial Vials
KOTRA PHARMA (M) SDN. BHD.
MAL16025035AZ METHYLPREDNISOLONE 1G FOR INJECTION COMPOSITION: Each vial contains: Methylprednisolone (as methylprednisolone sodium succinate) 1g PRESENTATION: A white or almost white, hygroscopic powder. The reconstituted solution is clear and colourless. INDICATIONS: Glucocorticoids should only be considered as a purely symptomatic treatment, unless in case of some endocrine disorders, where they are used as substitution treatment. _Anti-Inflammatory Treatment :_ _Rheumatic Disorders (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation) : _ _Collagen Diseases (during an exacerbation or as maintenance therapy in selected cases of) :_ _Dermatologic Diseases :_ _Allergic States (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in) : _ _Ophthalmic Diseases (severe acute and chronic allergic and inflammatory processes involving the eye) :_ _Gastrointestinal Diseases (to manage critical period of the disease in) :_ - Ulcerative colitis (systemic therapy) - Crohn’s disease (systemic therapy). _Respiratory Diseases :_ _Edematous States :_ - To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. _Immunosuppressive Treatment :_ Organ transplantation. _Treatment of Hematological and Oncological Disorders :_ _Hematologic Disorders :_ _Oncological Diseases (for palliative management of) :_ - Leukemias and lymphomas in adults - Acute leukemia of childhood. _Treatment of Shock States :_ Shock secondary to adrenocortical insufficiency or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present. (Hydrocortisone is generally the drug of choice. When mineralocorticoid activity is undesirable, methylprednisolone may be preferred.) Hemorrhagic, traumatic and surgical shock unresponsive to standard therapy. Although there are no well controlled (double-blind placebo) clinical trials, da Διαβάστε το πλήρες έγγραφο